ACRS · Aclaris Therapeutics, Inc. · Documents
$3.82
+0.03 (+0.66%)
At close · Oct 28
Return incl. dividend (before tax)
Q1 2024 earnings call transcript
Market Cap
$557.88M
Shares
147.20M
Volume · Oct 28
1.54M
Avg daily vol (3M)
2.85M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2026-10-27 | — | |
| 8-K | Aclaris Therapeutics reported ATI-052 achieved 45% placebo-adjusted EASI improvement at day 57 in atopic dermatitis and 59% FeNO reduction at day 15 in asthma, and plans a Phase 2b eosinophilic esophagitis trial in early 2027. | 2026-10-27 | — | |
| 10-Q | — | 2026-08-06 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | — | |
| 8-K | — | 2026-08-06 | — | |
| S-3ASR | — | 2026-08-06 | — | |
| Investor Event Transcript | — | 2026-06-04 | 2026-06-30 | |
| 8-K | — | 2026-06-04 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| 8-K | — | 2026-05-07 | — | |
| 8-K | — | 2026-04-28 | — | |
| DEF 14A | — | 2026-04-23 | 2026-06-04 | |
| DEFA14A | — | 2026-04-23 | — | |
| ARS | — | 2026-04-23 | 2025-12-31 | |
| Investor Event Transcript | — | 2026-04-14 | 2026-06-30 | |
| 8-K | — | 2026-03-11 | 2026-03-10 | |
| 8-K | — | 2026-03-10 | 2026-03-09 | |
| 10-K | — | 2026-02-26 | 2025-12-31 | |
| 8-K | — | 2026-02-26 | — | |
| 8-K | — | 2026-01-12 | — | |
| 8-K | — | 2026-01-06 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | — | |
| 8-K | — | 2025-10-14 | — | |
| 8-K | — | 2025-08-07 | — | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| 8-K | — | 2025-07-29 | — | |
| 8-K | — | 2025-06-30 | — | |
| 8-K | — | 2025-06-05 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| 8-K | — | 2025-05-08 | — | |
| ARS | — | 2025-04-24 | 2024-12-31 | |
| DEFA14A | — | 2025-04-24 | — | |
| DEF 14A | — | 2025-04-24 | 2025-06-05 | |
| PRE 14A | — | 2025-04-14 | 2025-06-05 | |
| S-3 | — | 2025-02-27 | — | |
| 10-K | — | 2025-02-27 | 2024-12-31 | |
| 8-K | — | 2025-02-27 | — | |
| 8-K | — | 2025-01-13 | — | |
| S-3 | — | 2024-12-19 | — | |
| 8-K | — | 2024-11-18 | 2024-11-16 | |
| 8-K | — | 2024-11-06 | — | |
| 10-Q | — | 2024-11-06 | 2024-09-30 | |
| 8-K | — | 2024-08-07 | — | |
| 10-Q | — | 2024-08-07 | 2024-06-30 | |
| 8-K | — | 2024-07-16 | — | |
| 8-K | — | 2024-06-07 | 2024-06-06 | |
| 10-Q | — | 2024-05-07 | 2024-03-31 | |
| 8-K | — | 2024-05-07 | — | |
| DEF 14A | — | 2024-04-25 | 2024-06-06 |
Showing 1–50 of 143 filings
Key facts
CIK
1557746
CUSIP
00461U105
13F (30d)
26 filings
21 filers
Visit website
Investor relations